Kringle Pharma Statistics
Total Valuation
Kringle Pharma has a market cap or net worth of JPY 4.28 billion. The enterprise value is 2.59 billion.
Important Dates
The last earnings date was Wednesday, November 11, 2026.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Kringle Pharma has 8.38 million shares outstanding. The number of shares has increased by 12.92% in one year.
| Current Share Class | 8.38M |
| Shares Outstanding | 8.38M |
| Shares Change (YoY) | +12.92% |
| Shares Change (QoQ) | +6.25% |
| Owned by Insiders (%) | 6.32% |
| Owned by Institutions (%) | 5.27% |
| Float | 6.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.89 |
| PB Ratio | 4.13 |
| P/TBV Ratio | 4.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.08 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.77, with zero debt.
| Current Ratio | 10.77 |
| Quick Ratio | 9.62 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -65.72% and return on invested capital (ROIC) is -41.13%.
| Return on Equity (ROE) | -65.72% |
| Return on Assets (ROA) | -25.09% |
| Return on Invested Capital (ROIC) | -41.13% |
| Return on Capital Employed (ROCE) | -45.30% |
| Weighted Average Cost of Capital (WACC) | 6.14% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 17 |
| Asset Turnover | 0.22 |
| Inventory Turnover | 0.33 |
Taxes
In the past 12 months, Kringle Pharma has paid 1.00 million in taxes.
| Income Tax | 1.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +22.61% in the last 52 weeks. The beta is 0.34, so Kringle Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | +22.61% |
| 50-Day Moving Average | 531.44 |
| 200-Day Moving Average | 426.28 |
| Relative Strength Index (RSI) | 47.26 |
| Average Volume (20 Days) | 309,730 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kringle Pharma had revenue of JPY 442.00 million and -813.00 million in losses. Loss per share was -105.23.
| Revenue | 442.00M |
| Gross Profit | 371.00M |
| Operating Income | -814.00M |
| Pretax Income | -812.00M |
| Net Income | -813.00M |
| EBITDA | n/a |
| EBIT | -814.00M |
| Loss Per Share | -105.23 |
Full Income Statement Balance Sheet
The company has 1.68 billion in cash and no debt, with a net cash position of 1.68 billion or 200.52 per share.
| Cash & Cash Equivalents | 1.68B |
| Total Debt | n/a |
| Net Cash | 1.68B |
| Net Cash Per Share | 200.52 |
| Equity (Book Value) | 1.17B |
| Book Value Per Share | 137.80 |
| Working Capital | 1.76B |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -563.00M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow Statement Margins
Gross margin is 83.94%, with operating and profit margins of -184.16% and -183.94%.
| Gross Margin | 83.94% |
| Operating Margin | -184.16% |
| Pretax Margin | -183.71% |
| Profit Margin | -183.94% |
| EBITDA Margin | n/a |
| EBIT Margin | -184.16% |
| FCF Margin | n/a |
Dividends & Yields
Kringle Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -12.92% |
| Shareholder Yield | -12.92% |
| Earnings Yield | -20.63% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Kringle Pharma has an Altman Z-Score of 1.62 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.62 |
| Piotroski F-Score | 2 |